Travere Q3 net income $150.7M from bile acid sale; FILSPARI sales $8M, 430 new starts

Travere Therapeutics, Inc.

2023-Q3 EPS reported -$0.29 revenue$100,179,000

Net income $150.7M ($1.97/share) includes gain from bile acid portfolio sale; prior year loss $69.7M.
FILSPARI net sales $8.0M in Q3, 430 new patient start forms (990 total since Feb 2023 launch).
R&D expense $60.6M, SG&A $67.8M; cash, equivalents & marketable securities $634.6M.
Regulatory: on track for sNDA for FILSPARI in IgAN (full approval) & FSGS in Q4; EU CHMP opinion year-end.
Completed sale of bile acid products to Mirum for up to $445M; pegtibatinase pivotal study to start by year-end.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Travere Therapeutics, Inc. reported financial results for the quarter ended September 30, 2023.

Period: the quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 7, 2023, Travere Therapeutics, Inc. (the “Company”) issued a press release announcing, among other things, its financial results for the quarter ended September 30, 2023.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Travere Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001438533-23-000046

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.